Results: 1-25 | 26-50 | 51-58

Table of contents of journal: *Cancer biotherapy & radiopharmaceuticals

Results: 1-25/58

Authors: OLDHAM RK
Citation: Rk. Oldham, INNOVATION IN SCIENCE, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 11(6), 1996, pp. 345-346

Authors: ORDER SE
Citation: Se. Order, EDITORS REVIEW, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 11(6), 1996, pp. 347-347

Authors: VERMA VN SHENOY CN NADKARNI JJ
Citation: Vn. Verma et al., AUGMENTATION OF CISPLATIN CYTOTOXICITY USING CYTOKINES ON CERVICAL-CARCINOMA CELL-LINES, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 11(6), 1996, pp. 349-354

Authors: BERGHELLA AM PELLEGRINI P DELBEATO T MACCARONE D ADORNO D CASCIANI CU
Citation: Am. Berghella et al., PROGNOSTIC-SIGNIFICANCE OF IMMUNOLOGICAL EVALUATION IN COLORECTAL-CANCER, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 11(6), 1996, pp. 355-361

Authors: KILLION JJ BUCANA CD RADINSKY R DONG ZY OREILLY T BILBE G TARCSAY L FIDLER IJ
Citation: Jj. Killion et al., MAINTENANCE OF INTESTINAL EPITHELIUM STRUCTURAL INTEGRITY AND MUCOSALLEUKOCYTES DURING CHEMOTHERAPY BY ORAL-ADMINISTRATION OF MURAMYL TRIPEPTIDE PHOSPHATIDYLETHANOLAMINE, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 11(6), 1996, pp. 363-371

Authors: CONTASTA I PELLEGRINI P BERGHELLA AM DELBEATO T CANOSSI A DIROCCO M ADORNO D CASCIANI CU
Citation: I. Contasta et al., NECESSITY OF BIOTHERAPEUTIC TREATMENTS INDUCING TH1 CELL FUNCTIONS INCOLORECTAL-CANCER, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 11(6), 1996, pp. 373-383

Authors: MIZUTANI Y OKADA Y YOSHIDA O BONAVIDA B
Citation: Y. Mizutani et al., SIGNIFICANCE OF CYTOTOXIC ACTIVITY OF PERIPHERAL-BLOOD LYMPHOCYTES AGAINST AUTOLOGOUS TUMOR-CELLS IN PATIENTS WITH BLADDER-CANCER, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 11(6), 1996, pp. 385-391

Authors: MAO XW ARCHAMBEAU JO GRIDLEY DS
Citation: Xw. Mao et al., IMMUNOTHERAPY WITH LOW-DOSE INTERLEUKIN-2 AND A POLYSACCHAROPEPTIDE DERIVED FROM CORIOLUS-VERSICOLOR, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 11(6), 1996, pp. 393-403

Authors: SOMAYAJI VV NAICKER SS SYKES TR GUAY V NOUJAIM AA
Citation: Vv. Somayaji et al., PREPARATION AND PROTEIN CONJUGATION OF A DIVINYL SULFONE DERIVATIZED BIFUNCTIONAL CHELATING AGENT, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 11(6), 1996, pp. 405-414

Authors: COOK CH HINKLE GH THURSTON MO MARTIN EW
Citation: Ch. Cook et al., PHARMACOKINETICS OF I-125 CC49 MONOCLONAL-ANTIBODY IN PATIENTS WITH COLON-CANCER, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 11(6), 1996, pp. 415-422

Authors: OLDHAM RK
Citation: Rk. Oldham, PROGRESS IN THE MONOCLONAL-ANTIBODY THERAPY OF CANCER, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 11(5), 1996, pp. 279-279

Authors: GORE M
Citation: M. Gore, THE ROLE OF INTERLEUKIN-2 IN CANCER-THERAPY, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 11(5), 1996, pp. 281-283

Authors: LISSONI P
Citation: P. Lissoni, PROGNOSTIC MARKERS IN INTERLEUKIN-2 THERAPY, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 11(5), 1996, pp. 285-287

Authors: NIEKEN J SLEIJFER DT BUTER J DELEIJ L MULDER NH
Citation: J. Nieken et al., OUTPATIENT-BASED SUBCUTANEOUS INTERLEUKIN-2 MONOTHERAPY IN ADVANCED RENAL-CELL CARCINOMA - AN UPDATE, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 11(5), 1996, pp. 289-295

Authors: TOURANI JM GRISE P LUCAS V MAYEUR D DUFOUR B DIPALMA M BOAZIZ C PAVLOVITCH JM PUJADELAURAINE E LARREGAIN D UNTEREINER M
Citation: Jm. Tourani et al., INTERLEUKIN-2 IN OUTPATIENTS WITH RENAL-CELL CARCINOMA - SCAPP1 TRIAL, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 11(5), 1996, pp. 297-300

Authors: SORET JY ESCUDIER B
Citation: Jy. Soret et B. Escudier, ADJUVANT TREATMENT WITH IL-2 OR INTERFERON-ALPHA IN RENAL-CELL CARCINOMA - A FRENCH MULTICENTRIC STUDY, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 11(5), 1996, pp. 301-302

Authors: RUEDA F MARTI F PARDO N BADELL I PEIRO M BERTRAN E VILLEN E GARCIA J CUBELLS J
Citation: F. Rueda et al., INTERLEUKIN-2 IN NEUROBLASTOMA - CLINICAL PERSPECTIVES BASED ON BIOLOGICAL STUDIES, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 11(5), 1996, pp. 303-308

Authors: JOFFE JK PATEL PM BANKS RE SELBY PJ
Citation: Jk. Joffe et al., CYTOKINES IN COMBINATION WITH CHEMOTHERAPY FOR ADVANCED RENAL-CARCINOMA - THE IMPORTANCE OF PATIENT SELECTION, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 11(5), 1996, pp. 309-313

Authors: ANTON P KIRCHNER H JONAS U ATZPODIEN J
Citation: P. Anton et al., CYTOKINES AND TUMOR VACCINATION, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 11(5), 1996, pp. 315-318

Authors: DECKERT M FRANZKE A BUER J PROBST M DUENSING S LOPEZHAENNINEN E KIRCHNER H POLIWODA H ATZPODIEN J
Citation: M. Deckert et al., LINOMIDE AND INTERLEUKIN-2 IN PATIENTS WITH ADVANCED RENAL-CELL CARCINOMA, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 11(5), 1996, pp. 319-324

Authors: KAIREMO KJA JEKUNEN AP BONDESTAM S KORPPITOMMOLA ET SAVOLAINEN S PAAVONEN T
Citation: Kja. Kairemo et al., DETECTION OF PSEUDOMYXOMA PERITONEI BY RADIOIMMUNOHISTOCHEMISTRY AND RADIOIMMUNOSCINTIGRAPHY, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 11(5), 1996, pp. 325-334

Authors: XIANG J MOYANA T MATTE G WILKINSON A ITZKOWITZ S QI YM
Citation: J. Xiang et al., ESTABLISHMENT OF A RAT COLONIC-CARCINOMA MODEL FOR STUDY OF IMMUNOREAGENTS AGAINST THE HUMAN TUMOR-ASSOCIATED TAG72 ANTIGEN, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 11(5), 1996, pp. 335-344

Authors: OLDHAM RK
Citation: Rk. Oldham, FDA REFORM - REAL OR JUST MORE POLITICS, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 11(4), 1996, pp. 227-228

Authors: QUAN WDY CASAL R ROSENFELD M WALKER PR
Citation: Wdy. Quan et al., ALPHA-INTERFERON-2B, LEUCOVORIN, AND 5-FLUOROURACIL (ALF) IN NONSMALLCELL LUNG-CANCER, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 11(4), 1996, pp. 229-234

Authors: INOUE T KIM EE WALLACE S YANG DJ WONG FCL BASSA P CHERIF A DELPASSAND E BUZDAR A PODOLOFF DA
Citation: T. Inoue et al., POSITRON EMISSION TOMOGRAPHY USING [F-18] FLUOROTAMOXIFEN TO EVALUATETHERAPEUTIC RESPONSES IN PATIENTS WITH BREAST-CANCER - PRELIMINARY-STUDY, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 11(4), 1996, pp. 235-245
Risultati: 1-25 | 26-50 | 51-58